VC

Clinical Trial of New Artificial Ventilation Pharmaceutical Begins

En
Clinical Trial of New Artificial Ventilation Pharmaceutical Begins

The Russian Foundation for Advanced Research Projects, in collaboration with Izmerov Research Institute of Occupational Health, being physically based at the Sklifosovsky Institute for Emergency Medicine, begins clinical trials for the new gas-liquid artificial ventilation pharmaceutical.

The gas-liquid artificial ventilation is an advanced method of treatment of bronchopulmonary diseases. Its development began in 2016. It was initially planned to be used for rescuing victims of deep-water transportation accidents; however, it was later established that it can be used in medicine for patients of all ages.

The method is based on using an oxygen-rich liquid, instead of air, to fill the patient’s lungs. The procedure ensures an intensive gas exchange, which is crucial for patients with poor lung function.

It should be noted that the research of the liquid breathing method began as early as 1970s in the USA and USSR. However, the method has not been approved for clinical practice, because no suitable pharmaceutical, which would ensure the necessary effect while not causing side effects, was developed. Additionally, integrating the method into general clinical practice requires the necessary equipment to be developed.

Both the pharmaceutical and the equipment for the procedure are currently undergoing trials in Russia. The animal testing has already been concluded, and the researchers have received the permission for clinical trials, as noted by the experts of The Russian Foundation for Advanced Research Projects. The Phases I-II of clinical trials are planned to be finished by late 2025.

Source: Russian Foundation for Advanced Research Projects